双鹭药业
(002038)
| 流通市值：59.35亿 | | | 总市值：71.61亿 |
| 流通股本：8.52亿 | | | 总股本：10.27亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 540,562,431.05 | 392,063,433.48 | 245,116,238.48 | 1,018,358,696.85 |
| 营业收入 | 540,562,431.05 | 392,063,433.48 | 245,116,238.48 | 1,018,358,696.85 |
| 二、营业总成本 | 461,951,501.39 | 261,700,152.08 | 136,620,657.72 | 765,793,318.81 |
| 营业成本 | 170,782,084.55 | 89,873,996.9 | 58,008,339.86 | 187,787,156.96 |
| 税金及附加 | 5,073,775.28 | 4,127,487.37 | 1,598,656.73 | 10,093,778.1 |
| 销售费用 | 91,222,553.23 | 48,797,538.62 | 17,035,038.54 | 271,596,840.2 |
| 管理费用 | 101,968,231.45 | 65,914,589.1 | 34,210,713.59 | 134,052,187.1 |
| 研发费用 | 98,929,930.35 | 57,415,748.19 | 28,053,862.46 | 177,106,511.15 |
| 财务费用 | -6,025,073.47 | -4,429,208.1 | -2,285,953.46 | -14,843,154.7 |
| 其中:利息收入 | 6,565,621.23 | 4,841,684.63 | 2,596,098.09 | 14,205,783.69 |
| 加:公允价值变动收益 | -121,662,443.96 | -118,495,945.17 | -44,049,648.74 | 205,211,215.43 |
| 加:投资收益 | 18,516,475.89 | 14,684,499.66 | 7,460,885.69 | 34,256,612.66 |
| 资产处置收益 | 1,142.29 | 507.6 | - | 13,331.22 |
| 资产减值损失(新) | - | - | - | -1,020,414.67 |
| 信用减值损失(新) | -13,442,742.02 | -13,375,014.04 | -4,633,715.93 | -25,570,243.06 |
| 其他收益 | 5,661,293.9 | 5,307,446.48 | 3,883,712.55 | 12,414,103.95 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -32,315,344.24 | 18,484,775.93 | 71,156,814.33 | 477,869,983.57 |
| 加:营业外收入 | 1.12 | 0.02 | 1,500.01 | 27,162.26 |
| 减:营业外支出 | 4,851,464.01 | 2,944.21 | - | 13,002,836.44 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -37,166,807.13 | 18,481,831.74 | 71,158,314.34 | 464,894,309.39 |
| 减:所得税费用 | -19,420,932.88 | -10,302,320.25 | 1,482,507.85 | 49,936,844.91 |
| 六、净利润 | -17,745,874.25 | 28,784,151.99 | 69,675,806.49 | 414,957,464.48 |
| 持续经营净利润 | -17,745,874.25 | 28,784,151.99 | 69,675,806.49 | 414,957,464.48 |
| 归属于母公司股东的净利润 | -16,735,581.13 | 29,590,001.31 | 70,134,618.06 | 416,691,942.89 |
| 少数股东损益 | -1,010,293.12 | -805,849.32 | -458,811.57 | -1,734,478.41 |
| (一)基本每股收益 | -0.02 | 0.03 | 0.07 | 0.41 |
| (二)稀释每股收益 | -0.02 | 0.03 | 0.07 | 0.41 |
| 八、其他综合收益 | - | - | - | 12,807,829.6 |
| 归属于母公司股东的其他综合收益 | - | - | - | 12,807,829.6 |
| 九、综合收益总额 | -17,745,874.25 | 28,784,151.99 | 69,675,806.49 | 427,765,294.08 |
| 归属于母公司股东的综合收益总额 | -16,735,581.13 | 29,590,001.31 | 70,134,618.06 | 429,499,772.49 |
| 归属于少数股东的综合收益总额 | -1,010,293.12 | -805,849.32 | -458,811.57 | -1,734,478.41 |
| 公告日期 | 2024-10-26 | 2024-08-26 | 2024-04-24 | 2024-04-24 |
| 审计意见(境内) | | | | 标准无保留意见 |